Manuel Mohr

Understanding what drives successful partnerships is critical for emerging oligonucleotide companies looking to secure investment, collaboration or acquisition opportunities. This candid panel will bring together pharma business development, external innovation and investment leaders to discuss what truly differentiates programs that attract strategic interest, from scientific validation and platform maturity to team capabilities and commercial potential.

• Hear directly from pharma BD and external innovation leaders on the scientific, technical and strategic signals that make an oligonucleotide programme stand out as a partnership opportunity
• Gain insight into how companies should position emerging platforms, technologies and assets to align with evolving pharma priorities and investment strategies
• Ask your questions directly and understand what decision-makers are evaluating when considering partnerships, collaborations and future opportunities